A Phase 3 interventional study of Ticagrelor 90 mg and Ticagrelor 60 mg in Myocardial Infarction, Cardiovascular Death and Atherothrombosis, sponsored by AstraZeneca. Completed at 847 sites in 31 countries. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-01-25.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ticagrelor in Myocardial Infarction — 3 open to participants now, 3 under way, 1 of them phase 3. Ticagrelor · Myocardial Infarction.
Among the 36 studies testing ticagrelor in Myocardial Infarction, this one has the largest enrollment, is the only one that started in 2010, is one of 11 in phase 3, and was the 4th registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →3 of the 36 studies testing ticagrelor in Myocardial Infarction are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 55+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 50 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21,379 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 132 across the 36 interventional studies. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Myocardial Infarction by AstraZeneca: none open now, none under way, none of them phase 3. Of 20 finished, 10 (50%) have results posted.
Among the 20 studies in Myocardial Infarction by AstraZeneca, this one has the largest enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2010, is one of 3 in phase 3, and was the 6th registered.
AstraZeneca’s Myocardial Infarction studies by the year they started, since 2000.
1 of the studies testing ticagrelor in Myocardial Infarction that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing ticagrelor in Myocardial Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Myocardial Infarction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Treatment
Drug: Ticagrelor 90 mg
Oral Treatment
Drug: Ticagrelor 60 mg
Oral Treatment
Drug: Ticagrelor Placebo
Oral dose twice a day
Oral dose twice a day
Oral dose twice a day
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization
Time frame: Randomization up to 47 months
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of \>= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug
Time frame: First dosing up to 48 months
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization
Time frame: Randomization up to 47 months
Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization
Time frame: Randomization up to 47 months
| Milestone | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo |
|---|---|---|---|
| Started | 7050 | 7045 | 7067 |
| Completed | 6995 | 6989 | 7014 |
| Not completed | 55 | 56 | 53 |
| Withdrew: Withdrawal by subject | 52 | 50 | 52 |
| Withdrew: Lost to follow-up | 3 | 6 | 1 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization
| Percentage of Patients | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo |
|---|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization | 7.8 | 7.8 | 9.0 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization
| Percentage of Patients | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo |
|---|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization | 2.9 | 2.9 | 3.4 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization
| Percentage of Patients | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo |
|---|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization | 5.1 | 4.7 | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of \>= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug
| Percentage of Patients | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo |
|---|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients | 2.6 | 2.3 | 1.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1,757/6,996 (25.1%) | 945/6,996 (13.5%) |
| Ticagrelor 60mg bd | — | 1,853/6,958 (26.6%) | 1,992/6,958 (28.6%) |
| Ticagrelor 90mg bd | — | 1,918/6,988 (27.4%) | 2,245/6,988 (32.1%) |
| Event | Placebo | Ticagrelor 60mg bd | Ticagrelor 90mg bd |
|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 109/6996 | 113/6958 | 115/6988 |
| Atrial fibrillationCardiac disorders | 67/6996 | 94/6958 | 74/6988 |
| PneumoniaInfections and infestations | 76/6996 | 69/6958 | 77/6988 |
| Cardiac failure congestiveCardiac disorders | 51/6996 | 53/6958 | 70/6988 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 59/6996 | 54/6958 | 54/6988 |
| Cardiac failureCardiac disorders | 58/6996 | 53/6958 | 54/6988 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 45/6996 | 39/6958 | 54/6988 |
| Angina pectorisCardiac disorders | 51/6996 | 45/6958 | 51/6988 |
| DeathGeneral disorders | 42/6996 | 34/6958 | 42/6988 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 37/6996 | 29/6958 | 38/6988 |
| Event | Placebo | Ticagrelor 60mg bd | Ticagrelor 90mg bd |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 329/6996 | 876/6958 | 1091/6988 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 165/6996 | 420/6958 | 505/6988 |
| Increased tendency to bruiseBlood and lymphatic system disorders | 65/6996 | 419/6958 | 464/6988 |
| ContusionInjury, poisoning and procedural complications | 111/6996 | 353/6958 | 385/6988 |
| NasopharyngitisInfections and infestations | 377/6996 | 364/6958 | 368/6988 |
| Age, Continuous(years) | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 65.4 ± 8.4 | 65.2 ± 8.4 | 65.4 ± 8.3 | 65.3 ± 8.3 |
| Sex: Female, Male(Participants) | Ticagrelor 90 mg | Ticagrelor 60 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 1682 | 1661 | 1717 | 5060 |
| Male | 5368 | 5384 | 5350 | 16102 |
Showing the first 100 of 847 sites across 31 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor